Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 31st, there was short interest totalling 129,700 shares, a growth of 118.4% from the May 15th total of 59,400 shares. Based on an average trading volume of 143,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.0% of the shares of the stock are short sold.
Shionogi & Co., Ltd. Price Performance
Shares of SGIOY stock traded up $0.01 during mid-day trading on Friday, reaching $8.55. The stock had a trading volume of 132,148 shares, compared to its average volume of 113,331. Shionogi & Co., Ltd. has a 12-month low of $6.22 and a 12-month high of $8.97. The company has a market cap of $14.55 billion, a P/E ratio of 14.40, a price-to-earnings-growth ratio of 2.37 and a beta of 0.18. The business has a 50-day simple moving average of $8.13 and a 200 day simple moving average of $7.56. The company has a current ratio of 7.64, a quick ratio of 7.01 and a debt-to-equity ratio of 0.01.
Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.03). Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. The firm had revenue of $721.77 million during the quarter, compared to analysts' expectations of $824.23 million. On average, sell-side analysts anticipate that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current year.
Shionogi & Co., Ltd. Company Profile
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Recommended Stories
Before you consider Shionogi & Co., Ltd., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. wasn't on the list.
While Shionogi & Co., Ltd. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
